1. Home
  2. TK vs SVRA Comparison

TK vs SVRA Comparison

Compare TK & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teekay Corporation

TK

Teekay Corporation

HOLD

Current Price

$10.70

Market Cap

1.0B

ML Signal

HOLD

Logo Savara Inc.

SVRA

Savara Inc.

HOLD

Current Price

$5.73

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TK
SVRA
Founded
1973
2007
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
1995
2009

Fundamental Metrics

Financial Performance
Metric
TK
SVRA
Price
$10.70
$5.73
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$7.33
AVG Volume (30 Days)
506.6K
1.8M
Earning Date
05-13-2026
05-13-2026
Dividend Yield
15.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$430.87
P/E Ratio
$13.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.12
$1.98
52 Week High
$14.38
$7.01

Technical Indicators

Market Signals
Indicator
TK
SVRA
Relative Strength Index (RSI) 32.98 60.63
Support Level $9.11 $4.77
Resistance Level $14.12 $6.15
Average True Range (ATR) 0.51 0.28
MACD -0.06 0.07
Stochastic Oscillator 8.14 69.28

Price Performance

Historical Comparison
TK
SVRA

About TK Teekay Corporation

Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: